Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Plus Pembrolizumab After PD-1/PD-L1 Failure in NSCLC
NCT03656094Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoint: Progression-free survival up to 60 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03656094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656094.